| ||||||||||||||
|
|
|||||||||||||

*Department of Anesthesia and Intensive Care, OLV-Hospital, Aalst, Belgium; and the
Outcomes ResearchTM Institute, and Department of Anesthesiology, University of Louisville, Louisville, Kentucky
Address correspondence to Jan De Witte, MD, Department of Anesthesia and Intensive Care, OLV-Hospital, Aalst, Belgium. Addess e-mail to jan.de.witte{at}olvz-aalst.be
| Introduction |
|---|
|
|
|---|
Because 5-HT3 receptors play a key role in pain transmission at the spinal level (3), the 5-HT3 antagonist ondansetron may decrease the efficacy of tramadol, as suggested in an abstract by Maroof et al.1
In that study, a small dose of 1 mg/kg tramadol was administered along with ondansetron 0.1 mg/kg or placebo, 15 min before the induction of anesthesia. Early postoperative pain scores differed significantly between the treatment groups. We therefore tested the hypothesis that the tramadol requirement by patient-controlled analgesia (PCA) may be increased when ondansetron is administered for antiemetic prophylaxis.
| Methods |
|---|
|
|
|---|
At induction of anesthesia, remifentanil 1 µg/kg was injected, followed by an infusion of 0.25 µg/kg/min until skin closure. A DiprifusorTM (AstraZeneca, Södertälje, Sweden) pharmacokinetic model (Fresenius Vial S. A., Brézius, France) was used for propofol infusion to a target plasma concentration of 4 µg/mL for intubation, which was adjusted thereafter to between 2 and 4 µg/mL. Atracurium was administered to facilitate endotracheal intubation. Tramadol, 2 mg/kg for 10 min, was given at discontinuation of remifentanil. A PCA pump (Pain Management Provider; Abbott Laboratories, North Chicago, IL) was programmed as follows: tramadol, 24 mg IV bolus; lockout time, 5 min; 4-h dose limit, 384 mg. The PCA system automatically recorded the doses.
Patients who required supplemental medication for analgesia could receive a single 100-mg tramadol top-up dose, or 5 mg piritramid, a synthetic opioid (Dipidolor®; Janssen Pharmaceutica, Beerse, Belgium). Simultaneous use of the PCA pump was always permitted. Nausea or vomiting was treated with alizapride 50100 mg IV. Patients in both study groups were given 2 g IV propacetamol (Prodafalgan®; Upsamedica s.a., Brussels, Belgium) at 6-h intervals after discharge from the recovery unit. Other analgesic or sedative drugs than those mentioned above, were prohibited.
Patients were observed for 4 h in the recovery unit by study nurses. Pain was evaluated at rest with a 100-mm long visual analog scale, where 0 mm represented no pain and 100 mm represented the worst imaginable pain. The degree of sedation was rated on a 4-point scale, and the presence of postoperative nausea and vomiting (PONV) was registered. A verbal retrospective pain score (4) was obtained 24 h after discharge from the recovery unit by using a 5-point scale. Overall satisfaction with pain relief was recorded.
Differences between the two groups were compared by using two-tailed unpaired t tests,
2 analysis, and Mann-Whitney ranked sum tests. The cumulative incidence of PONV was compared by using the log rank test. All results were presented as means ± SD; P < 0.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
|
|
|
| Discussion |
|---|
|
|
|---|
Our results suggest that tramadol will usually be effective when given at a rate near 24 mg/h (i.e., the bolus dose of our PCA system given hourly). The recommended maximum 24-hour dose of 400 mg of tramadol thus seems insufficiently large for treatment of severe acute postoperative pain.
Tramadol administration is associated with a disturbingly frequent incidence of PONV, which often leads to discontinuation of PCA (7). In a recent study, ondansetron failed to reduce the nausea associated with tramadol (8). Our results indicate that ondansetron 4 mg administered at the induction of anesthesia does not reduce the incidence of this complication in the recovery unit and later on. As an alternative for ondansetron, the administration of droperidol (an antiemetic with antidopaminergic activity) might be recommended. Droperidol suppresses PONV effectively in patients who receive tramadol PCA (9).
In conclusion, ondansetron decreases the analgesic effectiveness of tramadol. A single 4-mg dose of ondansetron given at the induction of anesthesia does not reduce the 24-h incidence of PONV.
| Acknowledgments |
|---|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
C. Dursteler, A. Mases, and M. M. Puig Universal PONV Prophylaxis in General Anesthesia: Should We Consider Its Immediate Implementation? Anesth. Analg., June 1, 2008; 106(6): 1922 - 1922. [Full Text] [PDF] |
||||
![]() |
P. F. White and P. S. A. Glass Universal PONV Prophylaxis in General Anesthesia: Should We Consider Its Immediate Implementation? Anesth. Analg., June 1, 2008; 106(6): 1922 - 1923. [Full Text] [PDF] |
||||
![]() |
A. Fassoulaki, A. Melemeni, M. Zotou, and C. Sarantopoulos Systemic Ondansetron Antagonizes the Sensory Block Produced by Intrathecal Lidocaine Anesth. Analg., June 1, 2005; 100(6): 1817 - 1821. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Finkel, J. B. Rose, M. L. Schmitz, P. K. Birmingham, G. A. Ulma, J. B. Gunter, A. Cnaan, C. J. Cote, R. A. Medve, and M. S. Schreiner An Evaluation of the Efficacy and Tolerability of Oral Tramadol Hydrochloride Tablets for the Treatment of Postsurgical Pain in Children Anesth. Analg., June 1, 2002; 94(6): 1469 - 1473. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. M. Stamer and F. Stuber Analgesic efficacy of tramadol if coadministered with ondansetron. Anesth. Analg., December 1, 2001; 93(6): 1626 - 1626. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|